Orlando, Fla.—Regulatory, legislative and industry action is needed to ensure future drug shortages do not have the same crippling effect on health systems as the current scarcity of small-volume parenterals (SVPs), experts said at the ASHP 2017 Midyear Clinical Meeting.
Manufacturers need to be more transparent in their production details; regulators and producers should have better contingency plans in place; and electronic health records (EHRs) should be designed to better adapt to